3/3/2020 7:17:54 AM
William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
3/2/2020 8:04:29 AM
Seattle Genetics Cancels Presentation And Webcast At
Cowen 40th Annual Healthcare Conference
2/19/2020 8:22:05 AM
Seattle Genetics And Astellas Receive FDA Breakthrough Therapy Designation For PADCEV(tm) With Pembrolizumab
2/11/2020 8:04:36 AM
Seattle Genetics And Astellas Pharma Announce Updated Results From Phase 1b/2 Clinical Trial EV-103
2/11/2020 7:28:19 AM
William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
2/7/2020 8:06:22 AM
William Blair Is Cutting Seattle Genetics Inc. (SGEN) FY22 Rev. Estimate To 790 M From 888 M
2/7/2020 8:06:11 AM
William Blair Is Lowering Seattle Genetics Inc. (SGEN) FY21 Rev. Estimate To 746 M From 831 M
2/7/2020 8:05:57 AM
William Blair Is Cutting Seattle Genetics Inc. (SGEN) FY20 Rev. Estimate To 694 M From 753 M
2/7/2020 8:05:21 AM
William Blair Is Cutting Seattle Genetics Inc. (SGEN) FY22 Estimate To -1.65 From 0.57
2/7/2020 8:05:00 AM
William Blair Is Cutting Seattle Genetics Inc. (SGEN) FY21 Estimate To -2.31 From -0.32
2/7/2020 8:04:44 AM
William Blair Is Lowering Seattle Genetics Inc. (SGEN) FY20 Estimate To -3.08 From -1.53
2/7/2020 8:03:16 AM
William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform
2/6/2020 4:06:49 PM
Seattle Genetics Q4 EPS $0.14 Vs. Loss $0.75 Year Ago
1/31/2020 8:04:33 AM
SGEN: EMA Validates MAA For Tucatinib For Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer